BNGO - バイオナノ・ジェノミクス （Bionano Genomics Inc.） バイオナノ・ジェノミクスBNGOのチャート
BNGOの企業情報
| symbol | BNGO |
|---|---|
| 会社名 | BioNano Genomics Inc （バイオナノ・ジェノミクス） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Biotechnology: Laboratory Analytical Instruments |
| 業種 | 先端医療機器_テクノロジ― IT・通信（IT_Communications） |
| 概要 | 事業概要 Bionano Genomics Inc. is a life sciences instrumentation company in the genome analysis space. The Company develops and markets the Saphyr system. The Company’s products include Sequencing for Discovery Research and Cytogenetics. Sequencing alone however is significantly limited due to its inability to reveal structural variations. Cytogenetics provide a clinical diagnosis cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes which is known as cytogenetics. Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response. バイオナノ・ジェノミクスは米国の計測機器メ―カ―。主にゲノム解析のライフサイエンス研究に使用される計測機器の製造・販売に従事する。研究者および臨床医が染色体の変化を研究し、超高感度で特異的な構造変化が検出できるプラットフォ―ム「Saphyr」システムを開発。同システムは検出機器、チップ、試薬と解析ツ―ルで構成。本社はカリフォルニア州サンディエゴ。 at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o |
| 本社所在地 | 9640 Towne Centre Drive Suite 100 San Diego CA 92121 USA |
| 代表者氏名 | David L. Barker デヴィッド・L・バーカー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 858-888-7600 |
| 設立年月日 | － |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.bionanogenomics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bngo |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -16.45547 |
| 終値（lastsale） | 6.5325 |
| 時価総額（marketcap） | 62002779.54 |
| 時価総額 | 時価総額（百万ドル） 65.87054 |
| 売上高 | 売上高（百万ドル） 10.74668 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 124.54237 |
| 当期純利益 | 当期純利益（百万ドル） -18.16421 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 BioNano Genomics Inc revenues increased 32% to $5.2M. Net loss decreased 42% to $7.2M. Revenues reflect EMEA segment increase of 27% to $1M Northern America segment increase of 6% to $1.9M. Lower net loss reflects Research and development decrease of 32% to $4.5M (expense) Other Non Operating I/E increase from $954K to $2.5M (income). |
BNGOのテクニカル分析
BNGOのニュース
Bionano Genomics'' Next-Gen Platform Set to Boost Throughput by 13x: Future of Cytogenetic Analysis Underway 2023/05/25 18:47:49 Benzinga
EF Hutton has initiated coverage of Bionano Genomics Inc (NASDAQ: BNGO ) with a Buy rating and a price target of $1.75 . The analyst says Bionano Genomics''s optical genome mapping (OGM) platform is well-positioned to disrupt cytogenetic analysis with its ability to reliably and efficiently detect Structural Variants (SV) across a comprehensive range of resolutions that existing techniques do not. BNGO targets a global market of 10,000 cytogenetic labs that analyze roughly 10 million DNA samples yearly in BNGO''s … Full story available on Benzinga.com
EF Hutton initiates coverage of Bionano Genomics at ''buy'' with a price target of $1.75 2023/05/25 11:11:47 Investing.com
https://www.investing.com/news/pro/bionano-genomics-receives-investment-bank-analyst-rating-update-3090863
Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich … or Broke. 2023/05/19 10:40:50 InvestorPlace
High-risk penny stocks have long tempted investors with the potential for significant returns. However, it is crucial to acknowledge the inherent risks associated with these speculative investments. If you’re investing in high-risk penny stocks, prepare for an exhilarating journey. It’s crucial to acknowledge the inherent risks involved in these speculative investments. This article will focus on three high-risk penny stocks with the potential for significant wealth accumulation. If you’re attracted to the allure of penny stocks, it’s vital to approach them with caution and conduct thorough research. While some penny stocks may present exciting growth prospects, others are filled with uncertainties and risks. ME 23andMe $2.04 BNGO Bionano Genomics $0.68 PGEN Precigen $1.24 23andMe Holding Company (ME) Source: nevodka / Shutterstock.com 23andMe (NASDAQ: ME ), a prominent genetic testing services company, has embarked on expansion endeavors. However, these initiatives have not been well-received by shareholders.
3 Growth Stocks That Are Disrupting Their Industries in 2023 2023/05/13 13:24:58 InvestorPlace
Everyone who invests in growth stocks hopes that one of their holdings will become the next Netflix (NASDAQ: NFLX ), the next Amazon (NASDAQ: AMZN ), or the next Facebook. In other words, they’re looking for names that can transform, or disrupt, entire sectors. I believe that in the current era, which features several truly transformative technologies — such as artificial intelligence, the Internet of Things, and improved renewable-energy systems — it’s easier than ever to find disruptive growth stock winners. Here are three growth stocks that are disrupting their industries. Because of these companies’ disruptive offerings, their stocks should soar over the longer term. And since the Street has frowned on most growth stocks for nearly two years, these names, along with many other of the best disruptive growth stock picks, are trading at very low valuations. Bionano (BNGO) Source: Dennis Diatel / Shutterstock.com Bionano’s (NASDAQ: BNGO ) optical genome mapping system, Saphyr, has consistently shown, in many studies, its ability to identify significantly more structural variations in DNA than standard tools.
Maxim Group maintains Bionano Genomics at ''buy'' with a price target of $3.00 2023/05/11 14:43:23 Investing.com
https://www.investing.com/news/pro/bionano-genomics-receives-investment-bank-analyst-rating-update-3080232
Better Gene Sequencing Stock: Illumina vs. Bionano Genomics 2023/05/06 12:00:00 The Motley Fool
This is a classic matchup of a grizzled top dog against a scrappy competitor.
Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal 2023/05/01 23:50:48 Benzinga
SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that on May 1, 2023, it published an open letter to stockholders in support of its proposals at its upcoming annual meeting of stockholders, a copy of which is included at the end of this press release. Details of the Annual Meeting of Stockholders The annual meeting of stockholders will be held virtually, via live webcast at www.virtualshareholdermeeting.com/BNGO2023 , on June 14, 2023, at 10:00 a.m. Pacific Time. Stockholders of record as of April 24, 2023, may vote at the annual meeting or by proxy over the telephone, through the internet or using the Notice of Internet Availability of Proxy Materials mailed to such stockholders. Stockholders may change their vote at any time before the final vote at the annual meeting. Details regarding voting procedures are included in the Company''s proxy statement for the annual meeting, filed with the U.S. Securities and Exchange Commission on April 28, 2023.
Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal 2023/05/01 23:50:00 Wallstreet:Online
SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that on May 1, 2023, it published an open letter to stockholders in support of its proposals at its upcoming annual meeting of stockholders, a copy of which is included at the end of this press release. Details of the Annual Meeting of Stockholders The annual meeting of stockholders
7 Growth Stocks With Huge Return Potential for Long-Term Investors 2023/04/25 20:55:49 InvestorPlace
Sooner or later, investors will stop fearing the “phantom recession,” i.e. the recession that really doesn’t exist except in many economists’ imaginations. At that point, many growth stocks should come soaring back. The latest evidence supporting my “phantom recession” theory came last week, when S&P reported that the U.S. private sector Purchasing Managers’ Index for April came in at 53.5 in April, up from 52.8 in March. Moreover, the nation’s Services PMI rose to 53.7, well above analysts’ average estimate of 51.5. Since services generate the lion’s share of U.S. economic output and the line between expansion and contraction among PMI stands at 50, the 53.7 reading indicates that the American economy is actually quite strong. That being said, and believing growth stocks will benefit from “phantom recession” realizations, here are some top stocks to consider. EVGO EVgo $5.80 BB BlackBerry $3.95 BNGO BioNano Genomics $0.74 CDNS Cadence Design Systems $203.40 ARRY Array Technologies $21.00 SCHW Charles Schwab $51.29 GM General Motors $32.93 EVgo ( EVGO ) Source: Sundry Photography / Shutterstock.com Electric vehicle charging company EVgo (NASDAQ: EVGO ) just reported a blowout fourth quarter.
Why Shares of Bionano Genomics Are Up Monday 2023/04/24 19:51:56 The Motley Fool
The life sciences company said it expects another improved quarter of revenue.
Watch this stock’s price performance: Bionano Genomics Inc. (NASDAQ:BNGO) 2023/01/23 20:00:00 US Post News
Currently, Bionano Genomics Inc.’s (BNGO) stock is trading at $1.92, marking a gain of 5.19% from last night’s close. At this price, the stock is -55.75% below its 52-week high of $4.35 and 65.95% above its 52-week low of $1.16. Based on the past 30-day period, the stock price is -4.29% below the high and […]
After Bionano Genomics Inc. (NASDAQ: BNGO) Surges -605.88% From Highs, What Will It Look Like? 2023/01/20 13:00:00 Marketing Sentinel
During the last session, Bionano Genomics Inc. (NASDAQ:BNGO)’s traded shares were 6.34 million, with the beta value of the company hitting 2.26. At the end of the trading day, the stock’s price was $1.70, reflecting an intraday loss of -7.10% or -$0.13. The 52-week high for the BNGO share is $4.35, that puts it down … After Bionano Genomics Inc. (NASDAQ: BNGO) Surges -605.88% From Highs, What Will It Look Like? Read More »
Bionano, Nvidia collaborate on data processing solution for genome mapping tool 2023/01/12 13:49:03 Seeking Alpha
Bionano Genomics (BNGO) is collaborating with Nvidia (NVDA) to develop an acceleration platform for use in Bionano''s optical genome mapping ((OGM)) workflow.The collaboration is…
Bionano to Accelerate Data Processing Solution for Optical Genome Mapping Workflow with NVIDIA 2023/01/12 13:00:00 GlobeNewswire
SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a collaboration with NVIDIA to develop an acceleration platform for use in Bionano’s optical genome mapping (OGM) workflow. This collaboration is expected to significantly improve data processing speed while reducing time and cost associated with secondary analysis of OGM data. The computation platform is designed to enable a small laboratory and information technology footprint, which would allow for rapid decentralized deployment.
Dear JAGX Stock Fans, Mark Your Calendars for Jan. 12 2023/01/11 17:08:31 InvestorPlace
Source: Spyro the Dragon/Shutterstock.com Fans of Jaguar Health (NASDAQ: JAGX ) stock will want to keep an eye on the company tomorrow as it prepares for an investor webcast . Investors will want to tune into that webcast as it will cover topics relevant to the company. That includes going over the unmet need associated with cancer therapy-related diarrhea (CTD). Breast cancer oncologist Lee Schwartzberg, MD, FACP, will discuss the topic. In addition to that, another topic of discussion will be Jaguar Health’s mental health Entheogen Therapeutics Initiative (ETI). This has it planning to discover novel, therapeutic opportunities derived from psychoactive plants. National Geographic Explorer-in-Residence Wade Davis, PhD, will cover this topic. The investor webcast is set to take place at 10:30 a.m. Eastern Time on Jan. 12, 2023. Investors that want to check out the webcast can register and participate by following this link . Other JAGX Stock News Today Jaguar Health also announced that Sandra M.